RJA
IBRX icon

Raymond James & Associates’s ImmunityBio IBRX Stock Holding History

Raymond James & Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$114K Buy
30,613
+2,000
+7% +$9.26K ﹤0.01% 3768
2024
Q2 		$181K Buy
28,613
+5,200
+22% +$34.3K ﹤0.01% 3629
2024
Q1 		$126K Buy
+23,413
New +$106K ﹤0.01% 3700
2021
Q1 		– Sell
-62,125
Closed -$828K – 4052
2020
Q4 		$828K Buy
+62,125
New +$598K ﹤0.01% 2462

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's IBRX Position: Q3 2024 in Review

Raymond James & Associates increased its ImmunityBio (IBRX) stake by 7% in Q3 2024, buying an estimated $9.26K and bringing the position to 30,613 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3768.

Raymond James & Associates first reported a position in IBRX in Q4 2020 and has held it in 4 quarters since. The position peaked at $828K in Q4 2020. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Raymond James & Associates held 30,613 shares of ImmunityBio worth $114K as of Q3 2024.
  • Raymond James & Associates bought 2,000 ImmunityBio shares in Q3 2024, an estimated $9.26K.
  • ImmunityBio made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3768 holding.
  • Raymond James & Associates first reported a position in ImmunityBio in Q4 2020 and has held it in 4 quarters since.
  • Raymond James & Associates's ImmunityBio position peaked at $828K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.